What to know about Bixlenvo, the new single-table HIV treatment option

In late August, 2026, the U.S. FDA approved a new single-table HIV treatment option: Bixlenvo, by Gilead Sciences. Here’s what to know about this new treatment, and what sets it apart from existing options. 

Bixlenvo joins other single-tablet HIV treatment heavy hitters including Biktarvy, Dovato, and Stribild on the shelf as one pill that delivers a complete HIV treatment. No additional pills are needed in many cases–we’ve come a long way since “drug-cocktails” were the standard. Once daily, single-tablet regimens have been a game changer for people living with HIV. 

However, people who have been living with HIV for many years, including long-term survivors and people who were born with HIV, are more likely to be on more complex HIV treatment regimens. They may be more likely to have HIV drug “resistance,” where some classes of HIV medications are less effective, and need to combine multiple pills or injections, or take their medication more frequently throughout the day.  

Enter: Bixlenvo, a complete one-tablet regimen for people who may be on more complex therapies. It isn’t intended for people newly starting HIV treatment. Rather, it’s only an option for folks to switch to, when they have their viral load controlled and suppressed with other medications, and fills a gap in treatment options for people who have resistance mutations and are currently taking more complex treatments.   

Bixlenvo is a two-drug combo pill, combining bictegravir and lenacapavir. (The brand name Bixlenvo is most certainly a Frankenstein of these two ingredient names.) 

Fun fact: when someone switches to Bixlenvo, they’ll take a few extra lenacapavir tablets at the beginning to make sure their drug levels are effective from the start.

Both bictegravir (an integrase strand transfer inhibitor) and lenacapavir (a capsid inhibitor) are powerful, potent HIV drugs. Bictegravir has a high barrier to resistance, and lenacapavir belongs to a new class of HIV drug, which means that most people won’t have any resistance to it.  

The fact that bictegravir is now being combined with lenacapavir is an exciting addition to HIV treatment options for treatment-experienced people, and I think that Bixlenvo may simplify HIV treatment for many long-term HIV survivors who have been on HIV treatments for years and have cycled through many drug classes throughout their lives. 

In the Phase 3 clinical trial (ARTISTRY-1) that tested how well Bixlenvo works for people living with HIV already on HIV treatment, participants were on average 60 years old, had been on HIV treatment for an average of 28 years, and were taking between two and 11 antiretroviral pills per day. More than half (67%) had a history of NRTI resistance, 55% had NNRTI resistance, and 41% had protease inhibitor resistance. 

Nearly all participants who switched from their current HIV treatment to Bixlenvo maintained HIV suppression (Bixlenvo proved “non-inferior” to existing complex regimens), the treatment was well tolerated, and participants experienced greater satisfaction from the new treatment.  

The actual form of the medication may be good news for some people as well. Although I haven’t seen the tablets of Bixlenvo yet, I hear they are fairly small for a single-tablet regimen (usually multi-drug pills are on the larger side). I don’t think this is going to be a blockbuster advantage, but some people will appreciate a smaller pill size.

Additionally, previously lenacapavir was only available to add to someone’s HIV treatment as an injection, which isn’t convenient for everyone. Having more options to provide medication with lenacapavir in tablet form will be advantageous.